A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Pertuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Trastuzumab
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PEONY
- Sponsors Roche
Most Recent Events
- 04 Jun 2024 Results aim to (1) describe the biomarker changes from baseline to surgical samples after HER2 targeted neoadjuvant therapy, and (2) explore the association of surgical biomarkers and DFS, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2022 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Status changed from recruiting to active, no longer recruiting.